• 2008

Company Description

EnzymeRx is a biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications.

EnzymeRx! a private, clinical stage biotechnology company developing uricase-PEG 20 for the treatment of resistant and refractory gout and related indications in which hyperuricemia plays a causative role. Our patented formulation of pegylated uricase is designed to have a long half life as well as reduced immunogenicity.